

### Remarks

Claims 1-13, 17, 19-21, 23-24, 28-29, 36-38, 41-58, 61, 63, 69, 71-73, 76, 81, and 96 were pending. No claims are added to cancelled. Therefore, claims 1-13, 17, 19-21, 23-24, 28-29, 36-38, 41-58, 61, 63, 69, 71-73, 76, 81, and 96 are still pending.

Support for the amendment to claim 1 can be found throughout the specification, for example, page 8, lines 9-11. Therefore, no new matter is added by this amendment.

Applicants elect Group I (claims 2-8, 17, 19, 23-24, 28-29, 36-38, 41-45, 48-58, 71-73, 76, 81 and 96), and the following species: use of the antiparallel beta-sheet fibers claimed in claim 1, the form of antiparallel beta-sheet fibers claimed in claim 11, the therapeutic applications claimed in claim 10, and the type of cells to be cultured on claimed in claim 61, with traverse. It is asserted in the Office action that Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because under PCT Rule 13.2, they lack the same or corresponding special technical features in view of Mihara *et al.* (US 2003/0162696). Applicants disagree and request reconsideration.

It is asserted in the Office action that Mihara *et al.* (US 2003/0162696) disclose antiparallel beta sheet fibres. However, Mihara *et al.* does not disclose the specific claimed class of peptides restricted to a net +/- 2 charge at pH 7.5. Indeed referring to the specification as filed on page 8 lines 5 to 19, the specific charge confers the special property of self-assembly which is not found with charges of +/- 3 or 4 net. Claim 1 has been amended to clarify the charge. Therefore, the claims make a contribution over the cited Mihara *et al.* document, and Applicants request reconsideration of the restriction requirement.

Upon the allowance of a generic claim, Applicant is entitled to consideration of claims to additional species (such as those listed in paragraphs 5-8 of the Office action) which depend or otherwise require all of the limitations of an allowable generic claim as provided by 37 C.F.R. § 1.141.


If there are any questions regarding this amendment, the Examiner is invited to telephone the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By

  
Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913